Use of Tissue Cross-reactivity Studies in the Development of Antibody-based Biopharmaceuticals
- 6 October 2010
- journal article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 38 (7) , 1138-1166
Abstract
Tissue cross-reactivity (TCR) studies are screening assays recommended for antibody and antibody-like molecules that contain a complementarity-determining region (CDR), primarily to identify off-target binding and, secondarily, to identify sites of on-target binding that were not previously identified. At the present time, TCR studies involve the ex vivo immunohistochemical (IHC) staining of a panel of frozen tissues from humans and animals, are conducted prior to dosing humans, and results are filed with the initial IND/CTA to support first-in-human clinical trials. In some cases, a robust TCR assay cannot be developed, and in these cases the lack of a TCR assay should not prevent a program from moving forward. The TCR assay by itself has variable correlation with toxicity or efficacy. Therefore, any findings of interest should be further evaluated and interpreted in the context of the overall pharmacology and safety assessment data package. TCR studies are generally not recommended for surrogate molecules or for comparability assessments in the context of manufacturing/cell line changes. Overall, the design, implementation, and interpretation of TCR studies should follow a case-by-case approach.Keywords
This publication has 44 references indexed in Scilit:
- Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpuraInternational Journal of Hematology, 2009
- Effect of Storage on p63 ImmunohistochemistryApplied Immunohistochemistry & Molecular Morphology, 2009
- Immunohistochemical ProtocolsAmerican Journal of Clinical Pathology, 2008
- Antigenicity testing by immunohistochemistry after tissue oxidationJournal of Clinical Pathology, 2007
- In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3Cancer Research, 2006
- Delineation of the Discontinuous-Conformational Epitope of a Monoclonal Antibody Displaying Fullin Vitroandin VivoThyrotropin ActivityMolecular Endocrinology, 2004
- Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptorsThe EMBO Journal, 2002
- The biology of the 17–1A antigen (Ep-CAM)Journal of Molecular Medicine, 1999
- The immunocytochemical localization of N-acetylaspartyl glutamate, its hydrolysing enzyme NAALADase, and the NMDAR-1 receptor at a vertebrate neuromuscular junctionNeuroscience, 1995
- Continuous and discontinuous protein antigenic determinantsNature, 1986